Vident Investment Advisory, LLC Arcus Biosciences, Inc. Transaction History

Vident Investment Advisory, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$15.96 - $23.15 $9,384 - $13,612	-588 Reduced 2.46%	23,276 $424,000
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $104,193 - $188,870	-5,289 Reduced 18.14%	23,864 $493,000
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $70,410 - $91,142	-3,031 Reduced 9.42%	29,153 $759,000
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $52,706 - $115,416	3,059 Added 10.5%	32,184 $815,000
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $140,406 - $203,084	4,855 Added 20.0%	29,125 $919,000
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $1.08 Million - $1.66 Million	-34,311 Reduced 58.57%	24,270 $982,000
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $112,675 - $157,653	-4,184 Reduced 6.67%	58,581 $2.04 Million
Q2 2021 Aug 13, 2021	BUY	$22.75 - $35.77 $173,377 - $272,603	7,621 Added 13.82%	62,765 $1.72 Million
Q1 2021 May 14, 2021	SELL	$26.16 - $41.39 $4,970 - $7,864	-190 Reduced 0.34%	55,144 $1.55 Million
Q4 2020 Feb 08, 2021	BUY	$17.0 - $32.36 $176,052 - $335,120	10,356 Added 23.02%	55,334 $1.44 Million
Q3 2020 Nov 12, 2020	SELL	$17.14 - $25.47 $55,225 - $82,064	-3,222 Reduced 6.68%	44,978 $771,000
Q2 2020 Jul 17, 2020	BUY	$13.97 - $36.56 $673,354 - $1.76 Million	48,200 New	48,200 $1.19 Million
Q4 2018 Feb 14, 2019	SELL	$9.74 - $14.5 $1.43 Million - $2.12 Million	-146,384 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.95 $106,134 - $145,837	-9,755 Reduced 6.25%	146,384 $2.04 Million
Q2 2018 Aug 14, 2018	BUY	$12.24 - $17.05 $1.91 Million - $2.66 Million	156,139 New	156,139 $1.91 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.